Developer docs
API playgroundTry for free, no card

Search company profiles

RNActive

Full company profile

uuid002dvc6

Namestring
RNActive
Legal namestring
BioNTech SE
Websiteurl
curevac.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

RNActive is a private for-profit biopharmaceutical company headquartered in Tübingen, Germany, founded in 2000. The firm is described as providing academic research and specialized development for RNA-based medicines, with a workforce of 251-500 employees. Its web presence is associated with CureVac's RNA platform under the URL curevac.com/rna-platform/rnactiver/, suggesting the RNActive technology is positioned within or aligned to CureVac's broader RNA technology offering.

The company's core activity centers on the research and development of RNA-based therapeutics, operating within the broader RNA medicines landscape alongside peers such as CureVac and BioNTech. The Tübingen location places RNActive within a recognized German biopharma and academic research cluster. The firmographic emphasis on "academic research" alongside medicines development implies a model that combines research services or academic collaboration with internal therapeutic pipeline development.

No specific products, clinical pipeline data, revenue figures, or partnership details were disclosed for RNActive in the available input. The company's go-to-market mechanics, pricing, and customer composition are not documented, limiting visibility into commercial operations. Data points aggregated under the RNActive company label in the input predominantly describe BioNTech (founded 2008, NASDAQ: BNTX, Cambridge MA) and are not applied to RNActive's description here.

Short descriptiontext

RNActive is a private Tübingen-based biopharmaceutical company founded in 2000, employing 251-500 people to conduct academic research and develop RNA-based medicines, with technology aligned to CureVac's RNA platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersTübingen, Germany
HQ citystring
Tübingen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical research, RNA-based medicines, academic research services, drug development, therapeutic development
Industry4 codes
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
Product category
RNA Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Products and Vaccines
TypeOne Time License
Description

Revenue from approved pharmaceutical products including COVID-19 vaccines and pipeline therapeutic products for cancer and infectious diseases. Products are distributed through healthcare systems, hospitals, clinics, and pharmacies globally.

biontech.com
2Clinical Development and Licensing
TypeLicensing Royalties
Description

Revenue from clinical development partnerships, licensing agreements, and co-development collaborations for pipeline candidates across oncology and infectious disease programs.

biontech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1BNT327
Description

Next-generation bispecific antibody candidate that binds to both PD-L1 and VEGF-A, acting on two validated biological mechanisms against cancer in a synergistic manner.

biontech.com
Core offering1 text field

RNActive is a biopharmaceutical company providing academic research and specialized development for RNA-based medicines. The company operates in Tübingen, Germany and focuses on advancing RNA-based therapeutic platforms and the development of novel medicines built on RNA biology expertise.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • €2.10 billion invested in R&D in 2025 for cancer care across high-incidence indications
+2 more records
Product overview1 text field

BioNTech operates a diversified immunotherapy platform consisting of three complementary therapeutic modalities: mRNA cancer immunotherapies (individualized and shared neoantigen approaches), next-generation immunomodulators (including BNT327 bispecific antibody), and targeted therapies. The company executes a combination strategy aiming to develop new therapies based on synergistic modalities for cancer treatment across the continuum from adjuvant to advanced/metastatic settings. Additionally, the platform extends to infectious disease vaccines leveraging mRNA technology.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Arcturus is a clinical-stage mRNA medicines and siRNA therapeutics company with a comparable platform-based business model and similar indication breadth in vaccines and rare disease.

TypeDirect peer
Description

BioNTech is a German-headquartered mRNA therapeutics and immunotherapy company. It is directly comparable to RNActive on modality, geography, and pipeline focus in mRNA cancer immunotherapies and infectious disease vaccines.

TypeEmerging player
Description

Kernal Biologics is an mRNA therapeutics company focused on cancer immunotherapy and is comparable to RNActive as an emerging mRNA oncology platform with narrower commercial scale.

4Translate Bio (Pfizer)
TypeDirect peer
Description

Translate Bio develops mRNA therapeutics for diseases of the lung and liver and is now part of Pfizer. It is comparable to RNActive as an mRNA platform company developing nucleic-acid-based medicines.

TypeEmerging player
Description

Pantherna Therapeutics is a German mRNA therapeutics company focused on regenerative medicine and tissue-specific mRNA delivery, comparable as a European early-stage mRNA platform peer.

TypeEmerging player
Description

Tiba Biotech is an RNA therapeutics company developing engineered RNAi and mRNA delivery technologies for infectious disease and oncology, comparable as an emerging RNA platform peer.

7Ethris
TypeDirect peer
Description

Ethris is a Munich-based mRNA therapeutics company focused on pulmonary and respiratory indications using stabilized non-immunogenic mRNA. It is directly comparable as a European-headquartered mRNA platform peer.

TypeDirect peer
Description

Moderna is a leading mRNA therapeutics company developing vaccines and therapeutics across infectious disease, oncology, and rare diseases. It is directly comparable to RNActive as a modality-aligned mRNA platform company competing in the same technology category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RNActive

RNA Therapeuticscurevac.com

RNActive is a private Tübingen-based biopharmaceutical company founded in 2000, employing 251-500 people to conduct academic research and develop RNA-based medicines, with technology aligned to CureVac's RNA platform.

What RNActive does

RNActive is a private for-profit biopharmaceutical company headquartered in Tübingen, Germany, founded in 2000. The firm is described as providing academic research and specialized development for RNA-based medicines, with a workforce of 251-500 employees. Its web presence is associated with CureVac's RNA platform under the URL curevac.com/rna-platform/rnactiver/, suggesting the RNActive technology is positioned within or aligned to CureVac's broader RNA technology offering.

The company's core activity centers on the research and development of RNA-based therapeutics, operating within the broader RNA medicines landscape alongside peers such as CureVac and BioNTech. The Tübingen location places RNActive within a recognized German biopharma and academic research cluster. The firmographic emphasis on "academic research" alongside medicines development implies a model that combines research services or academic collaboration with internal therapeutic pipeline development.

No specific products, clinical pipeline data, revenue figures, or partnership details were disclosed for RNActive in the available input. The company's go-to-market mechanics, pricing, and customer composition are not documented, limiting visibility into commercial operations. Data points aggregated under the RNActive company label in the input predominantly describe BioNTech (founded 2008, NASDAQ: BNTX, Cambridge MA) and are not applied to RNActive's description here.

RNActive firmographics

Firmographics
Name
RNActive
Legal name
BioNTech SE
Website
https://curevac.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
RNActive is a private Tübingen-based biopharmaceutical company founded in 2000, employing 251-500 people to conduct academic research and develop RNA-based medicines, with technology aligned to CureVac's RNA platform.
Ownership category
akta.pro rank

RNActive industry classification

Industry
Product category
RNA Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Biopharmaceutical research
  • RNA-based medicines
  • Academic research services
  • Drug development
  • Therapeutic development

Where RNActive is headquartered

Location

Headquarters

HQ city
Tübingen
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

RNActive business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Products and Vaccines: Revenue from approved pharmaceutical products including COVID-19 vaccines and pipeline therapeutic products for cancer and infectious diseases. Products are distributed through healthcare systems, hospitals, clinics, and pharmacies globally.
  2. Clinical Development and Licensing: Revenue from clinical development partnerships, licensing agreements, and co-development collaborations for pipeline candidates across oncology and infectious disease programs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

RNActive product offering

Product offering

Core offering

RNActive is a biopharmaceutical company providing academic research and specialized development for RNA-based medicines. The company operates in Tübingen, Germany and focuses on advancing RNA-based therapeutic platforms and the development of novel medicines built on RNA biology expertise.

Product overview

BioNTech operates a diversified immunotherapy platform consisting of three complementary therapeutic modalities: mRNA cancer immunotherapies (individualized and shared neoantigen approaches), next-generation immunomodulators (including BNT327 bispecific antibody), and targeted therapies. The company executes a combination strategy aiming to develop new therapies based on synergistic modalities for cancer treatment across the continuum from adjuvant to advanced/metastatic settings. Additionally, the platform extends to infectious disease vaccines leveraging mRNA technology.

Differentiator

Problem solved

Functional benefit

Brands

  • BNT327: Next-generation bispecific antibody candidate that binds to both PD-L1 and VEGF-A, acting on two validated biological mechanisms against cancer in a synergistic manner.

Quantifiable outcome

  • €2.10 billion invested in R&D in 2025 for cancer care across high-incidence indications
  • +2 more outcomes

Companies that use RNActive

Customer profile

Segments3 records

Ideal customer profiles1 record

RNActive technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

RNActive partnerships and signals

Strategic signal

Scale indicators4 records

Expansion highlights2 records

RNActive competitors and assessment

Company assessment

Direct peers

  • Arcturus Therapeutics: Arcturus is a clinical-stage mRNA medicines and siRNA therapeutics company with a comparable platform-based business model and similar indication breadth in vaccines and rare disease.
  • BioNTech: BioNTech is a German-headquartered mRNA therapeutics and immunotherapy company. It is directly comparable to RNActive on modality, geography, and pipeline focus in mRNA cancer immunotherapies and infectious disease vaccines.
  • Translate Bio (Pfizer): Translate Bio develops mRNA therapeutics for diseases of the lung and liver and is now part of Pfizer. It is comparable to RNActive as an mRNA platform company developing nucleic-acid-based medicines.
  • Ethris: Ethris is a Munich-based mRNA therapeutics company focused on pulmonary and respiratory indications using stabilized non-immunogenic mRNA. It is directly comparable as a European-headquartered mRNA platform peer.
  • Moderna: Moderna is a leading mRNA therapeutics company developing vaccines and therapeutics across infectious disease, oncology, and rare diseases. It is directly comparable to RNActive as a modality-aligned mRNA platform company competing in the same technology category.

Emerging players

  • Kernal Biologics: Kernal Biologics is an mRNA therapeutics company focused on cancer immunotherapy and is comparable to RNActive as an emerging mRNA oncology platform with narrower commercial scale.
  • Pantherna Therapeutics: Pantherna Therapeutics is a German mRNA therapeutics company focused on regenerative medicine and tissue-specific mRNA delivery, comparable as a European early-stage mRNA platform peer.
  • Tiba Biotech: Tiba Biotech is an RNA therapeutics company developing engineered RNAi and mRNA delivery technologies for infectious disease and oncology, comparable as an emerging RNA platform peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

RNActive social profiles

Digital presence

RNActive financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RNActive leadership team

Management profile

Number of profiles

RNActive funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RNActive M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RNActive

What does RNActive do?

RNActive is a biopharmaceutical company providing academic research and specialized development for RNA-based medicines. The company operates in Tübingen, Germany and focuses on advancing RNA-based therapeutic platforms and the development of novel medicines built on RNA biology expertise.

Is RNActive a public or private company?

RNActive is a public company. It is classified as corporate owned and is currently operating.

When was RNActive founded?

RNActive was founded in 2008. It employs 1,001 to 5,000 people.

Where is RNActive based?

RNActive is headquartered in Tübingen, Germany, in the Europe region.

How does RNActive make money?

Two revenue lines are on record. Pharmaceutical Products and Vaccines are the primary driver. The others are clinical Development and Licensing.

Who are RNActive's main competitors?

Direct peers on record are Arcturus Therapeutics, BioNTech, Translate Bio (Pfizer), Ethris and Moderna. Emerging players are Kernal Biologics, Pantherna Therapeutics and Tiba Biotech.

Does RNActive have an API?

No public API is recorded for RNActive.

What industry is RNActive in?

RNActive's product category is RNA Therapeutics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales